Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Solulink Completes Equity Financing for HybriLink™ Antibody-Labeling Technology

Published: Friday, July 19, 2013
Last Updated: Friday, July 19, 2013
Bookmark and Share
New funding advances mission to provide flow cytometry users with a solution to the ‘missing color’ problem.

Solulink, Inc. announced the completion of a new round of equity financing. The funds will enable Solulink to accelerate the commercialization of its HybriLink ‘any antibody in any color’ labeling technology. The HybriLink technology satisfies flow cytometrists’ unmet needs and enables antibody suppliers to address market demand for greater flow cytometry multiplexing ease and convenience.

The HybriLink technology solves the ‘missing color’ problem: the inability to find the needed antibody labeled with the right fluorophore (color). Often, the desired combination is not commercially available. By providing a simple way to mix and match any fluorophore with any antibody on demand, just-in-time at the point-of-use, HybriLink dramatically streamlines the development and expansion of multicolor flow panels for flow cytometry research labs. Solulink believes that HybriLink’s ability to offer all antibodies in all fluorophores – including the next generation of emerging fluorophores – resolves a fundamental challenge in flow cytometry and will expand the overall flow cytometry reagents market size.

“With the HybriLink technology, antibodies are labeled with a tag and the fluorophores labeled with a complimentary tag. These two components are then combined to form the labeled antibody, ready to use with nearly 100% efficiency. Labeled-antibody providers can now supply tagged antibodies and complimentary tagged fluorophores, which allow the user to create an unlimited number of labeled antibodies,” said Solulink’s CEO, David McCarty.

“Solulink’s HybriLink technology simultaneously fulfills two increasingly critical needs in flow cytometry: HybriLink offers flow cytometrists an easy way to create, or optimize, multi-color flow panels on demand by labeling any antibody with any color, without chemistry or chromatography. In addition, HybriLink offers strategic partners a radically simplified way to introduce new fluorophores into their library of labeled antibodies, while expanding their market potential.”

The company is currently providing early access to HybriLink products to select customers. Attractive licensing terms are available for licensees and commercial partners in the flow cytometry and antibody reagents markets.

“Flow cytometry instruments and fluorophores have advanced rapidly; however, antibody-labeling technology has stagnated and the few advances have not met user or market expectations,” added Mark Horne, CEO, Plymouth Ventures. “Based on our diligence results, we are confident that the HybriLink technology represents a major advancement for flow cytometry and will be embraced by the research community.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Former Life Technologies and BD Biosciences Executive John L. “Kip” Miller Joins Solulink’s Board of Directors
Mr. Miller brings a successful track record of life science leadership and in-depth knowledge of the life science and flow cytometry markets to Solulink’s Board.
Wednesday, September 04, 2013
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Using Gene-editing Technology for Faster, Cheaper Antiviral Drug Development
UCLA scientists are working to develop special screening libraries based on a gene-editing technology called CRISPR.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!